Bayer Consumer Health Journey Still Short Of Destination
Executive Summary
Bayer says issues encountered after acquiring Merck & Co.’s consumer brands two years ago have meant slower growth than expected. But it suggests that’s not a precedent for its planned mega-merger with Monsanto.
You may also be interested in...
Bayer ‘All Hands On Deck’ For US Consumer Business Turnaround
“There is a ton of work still for us to do,” Erica Mann, Bayer’s global consumer head, said after the firm reported disappointing second-quarter results. The root of the problem is over-estimating the revenue boost from former Merck & Co. brands, the firm says.
Bayer ‘All Hands On Deck’ For US Consumer Business Turnaround
“There is a ton of work still for us to do,” Erica Mann, Bayer’s global consumer head, said after the firm reported disappointing second-quarter results. The root of the problem is over-estimating the revenue boost from former Merck & Co. brands, the firm says.
Bayer Plans 19 Consumer Product Launches To Revive Sluggish Sales
Bayer consumer readies 19-product pipeline for 2017 as it works to increase sales of brands including Coppertone and Dr. Scholl’s brands that have been sluggish since being acquired from Merck & Co.